Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Oral antidiabetic drug modulates the body's nitrogen and urea metabolism

The most frequently prescribed oral antidiabetic drug metformin significantly affects metabolic pathways.

14 Sep 2016

Diabetes drug linked to decreased weight gain in children with autism spectrum disorder

The diabetes medication metformin hydrochloride was associated with decreased weight gain in a small clinical trial of children and adolescents with autism spectrum disorder who were taking atypical antipsychotics to treat symptoms of irritability and agitation, according to an article published online by JAMA Psychiatry.

24 Aug 2016

Specific molecular features control uptake of biguanides into mitochondria to inhibit respiration

The biguanides are a family of drugs with diverse clinical applications. Metformin, a widely used anti-hyperglycemic biguanide, suppresses mitochondrial respiration by inhibiting respiratory complex I. Phenformin, a related anti-hyperglycemic biguanide, also inhibits respiration, but proguanil, which is widely used for the prevention of malaria, does not.

12 Aug 2016

Metabolic-checkpoint inhibitor combination approach may improve cancer therapies

Reprogramming of the molecular pathways underlying normal metabolism is essential for T cell infection-fighting function and for the immune system to form a "memory" of the microbes it has already encountered. But exactly how metabolism in exhausted T cells is maintained in chronic infections and cancer is a missing element in this line of research.

3 Aug 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Common drug for type 2 diabetes may play surprising role in preventing preterm birth

Metformin, a medication routinely used by millions of people with type 2 diabetes, may also play an unexpected role in blocking a significant cause of preterm birth, according to research findings published July 25.

26 Jul 2016

Risk of hypoglycemia differs between SU agents, study reveals

Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs-which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide-stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body.

20 Jul 2016

Diabetes drug metformin could help reduce toxic acid levels linked to MSUD

Maple Syrup Urine Disease (MSUD) is a rare inherited metabolic disorder involving the dysfunction of an enzyme which breaks down three essential amino acids: leucine, isoleucine and valine.

6 Jul 2016

Experimental lipid-lowering drug improves glucose control in diabetic patients

High triglycerides -- a type of fat, or lipid, in the blood -- increase the risk of heart disease and perhaps type 2 diabetes. For the first time, it has been shown that profoundly lowering triglycerides in diabetics improves their insulin sensitivity over time, which helps them maintain healthy glucose - blood sugar -- levels.

28 Jun 2016

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Researchers have shown that the glucose-lowering drug liraglutide safely and effectively decreases the overall risk of heart attack, stroke, or cardiovascular death for people with type 2 diabetes.

14 Jun 2016

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Empagliflozin has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

6 Jun 2016

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial.

6 Jun 2016

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology.

6 Jun 2016

New NPS MedicineWise program aims to help health professionals improve diabetes management

A new educational program aims to help health professionals keep up to date with the latest evidence on second and third line medicines for lowering blood glucose.

2 Jun 2016

Cardioprotective effect proposed for metformin

A large retrospective analysis suggests that metformin could be cardioprotective in insulin-dependent patients with Type 2 diabetes.

21 May 2016

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research.

17 May 2016

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

Oral regimens could offer simple solution for severe hyperglycaemia

Study findings indicate that oral treatments could offer a simpler alternative to upfront insulin for patients who have severe hyperglycaemia at the time of diagnosis with Type 2 diabetes.

10 May 2016

New fruit fly model study reveals metabolic pathway that can be targeted to treat FXS patients

Fragile X syndrome (FXS) is the most common genetically inherited cause of intellectual disability in humans. New research shows how the hormone insulin -- usually associated with diabetes -- is involved in the daily activity patterns and cognitive deficits in the fruitfly model of FXS, according to a new study from the Perelman School of Medicine at the University of Pennsylvania published online this month in Molecular Psychiatry in advance of the print issue.

27 Apr 2016

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.

26 Apr 2016

Metformin News and Research

Further Reading

Oral antidiabetic drug modulates the body's nitrogen and urea metabolism

Diabetes drug linked to decreased weight gain in children with autism spectrum disorder

Specific molecular features control uptake of biguanides into mitochondria to inhibit respiration

Metabolic-checkpoint inhibitor combination approach may improve cancer therapies

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

Common drug for type 2 diabetes may play surprising role in preventing preterm birth

Risk of hypoglycemia differs between SU agents, study reveals

Diabetes drug metformin could help reduce toxic acid levels linked to MSUD

Experimental lipid-lowering drug improves glucose control in diabetic patients

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

New research reveals advances that could change gynecologic cancer standard-of-care treatments

New NPS MedicineWise program aims to help health professionals improve diabetes management

Cardioprotective effect proposed for metformin

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Clinical study shows sitagliptin drug not effective in treating NAFLD

Oral regimens could offer simple solution for severe hyperglycaemia

New fruit fly model study reveals metabolic pathway that can be targeted to treat FXS patients

GLP-1 receptor agonist may benefit high-risk diabetes

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News